Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 81, Issue -, Pages 142-160Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2014.10.031
Keywords
MicroRNA; Drug delivery; Non-viral vector; Synthetic vector; Cancer therapy
Categories
Funding
- National Basic Research Program of China (973 Program) [2014CB931902, 2013CB932503]
- NSFC, China [81172996, 81373357, 81422048, 81402883]
- Chinese Postdoctoral Science Foundation [2012M510097, 2013T60478]
Ask authors/readers for more resources
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. Because of significant changes in their expression in cancer, miRNAs are believed to be key factors in cancer genetics and to have potential as anticancer drugs. However, the delivery of miRNAs is limited by many barriers, such as low cellular uptake, immunogenicity, renal clearance, degradation by nucleases, elimination by phagocytic immune cells, poor endosomal release, and untoward side effects. Nonviral delivery systems have been developed to overcome these obstacles. In this review, we provide insights into the development of non-viral synthetic miRNA vectors and the promise of miRNA-based anticancer therapies, including therapeutic applications of miRNAs, challenges of vector design to overcome the delivery obstacles, and the development of miRNA delivery systems for cancer therapy. Additionally, we highlight some representative examples that give a glimpse into the current trends into the design and application of efficient synthetic systems for miRNA delivery. Overall, a better understanding of the rational design of miRNA delivery systems will promote their translation into effective clinical treatments. (C) 2014 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available